Regeneron Pharmaceuticals, Inc. (REGN) to Issue Quarterly Dividend of $0.88 on March 20th

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) declared a quarterly dividend on Monday, February 17th,RTT News reports. Stockholders of record on Thursday, February 20th will be paid a dividend of 0.88 per share by the biopharmaceutical company on Thursday, March 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.52%. The ex-dividend date is Thursday, February 20th.

Regeneron Pharmaceuticals Trading Down 0.1 %

Shares of REGN opened at $673.60 on Tuesday. Regeneron Pharmaceuticals has a 1-year low of $642.00 and a 1-year high of $1,211.20. The firm has a 50 day simple moving average of $704.64 and a 200-day simple moving average of $891.91. The stock has a market cap of $74.02 billion, a price-to-earnings ratio of 17.60, a price-to-earnings-growth ratio of 2.38 and a beta of 0.08. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 4.46.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals’s revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the business earned $11.86 earnings per share. Equities analysts forecast that Regeneron Pharmaceuticals will post 36.67 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

REGN has been the topic of a number of research analyst reports. JPMorgan Chase & Co. reduced their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a report on Thursday, October 24th. Citigroup dropped their price target on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Barclays dropped their target price on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Piper Sandler dropped their target price on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research report on Monday, January 27th. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.